Study on immunity of dengue virus and dengue vaccine development

doi:10.1007/s11515-008-0015-8

Front Biol Chin

2009, Vol. 4

Issue (2) : 125-128 https://doi.org/10.1007/s11515-008-0015-8

REVIEW

Study on immunity of dengue virus and dengue vaccine development

Xiaofang WANG, Xiaoxia HUANG, Shiwen WANG(

)

State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China

Download: PDF(76 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

In the study of vaccines for dengue viruses, which are multivalent immunization, genetically and antigenically distinct, we should have more sophisticated understanding of viral immune physiology. Because the immune response to dengue and its role in the pathophysiology of dengue fever and dengue hemorrhagic fever are multifaceted, several different efforts have been made to engineer a protective vaccine. Because of space limitations, this review is focused only on vaccines that have emerged from preclinical studies into clinical trial.

Keywords dengue fever immunology T cells vaccines

Corresponding Author(s): WANG Shiwen,Email:wangshiwencdc@163.com

Issue Date: 05 June 2009

Cite this article:

Xiaofang WANG,Xiaoxia HUANG,Shiwen WANG. Study on immunity of dengue virus and dengue vaccine development[J]. Front Biol Chin, 2009, 4(2): 125-128.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-008-0015-8
https://academic.hep.com.cn/fib/EN/Y2009/V4/I2/125

1	Durbin A P, Karron R A, Sun W, Vaughn D W, Reynolds M J, Perreault J R, Thumar B, Men R, Lai C J, Elkins W R, Chanock R M, Murphy B R, Whitehead S S (2001). Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3’-untranslated region. Am J Trop Med Hyg , 65: 405-413
2	Durbin A P, Whitehead S S, McArthur J, Perreault J R (2005). rDEN4?30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis , 191: 710-718
3	Edelman R (2007). Dengue vaccines approach the finish line. Clin Infect Dis , 45 (Suppl 1): S56-60
4	Halstead S B (2007). Dengue. Lancet , 370(9599): 1644-1652
5	Hatch S, Mathew A, Rothman A (2008). Dengue vaccine: opportunities and challenges. IDRUGS , 11(1): 42-45
6	Holman D H, Wang D, Raviprakash K, Raja N U, Luo M, Zhang J, Porter K R, Dong J Y (2007). Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol , 14(2): 182-189
7	Kaufman B M, Summers P L, Dubois D R, Cohen W H, Gentry M K, Timchak R L, Burke D S, Eckels K H (1989). Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg , 41(5): 576-580
8	Kautner I, Robinson M J, Kuhnle U (1997). Dengue virus infection: Epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr , 131(4): 516-524
9	Kliks S C, Nisalak A, Brandt W E, Wahl L, Burke D S (1989). Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg , 40: 444-451
10	Kurane I, Brinton M A, Samson A L, Ennis F A (1991). Dengue virus-specific, human CD4⁺, CD8^-cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol , 65(4): 1823-1828
11	Lai C Y, Tsai W Y, Lin S R, Kao C L, Hu H P, King C C, Wu H C, Chang G J, Wang W K (2008). Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol , 82(13): 6631-6643
12	Livingston P G, Kurane I, Lai C J, Bray M, Ennis F A (1994). Recognition of envelope protein by dengue virus serotype-specific human CD4⁺, CD8^-cytotoxic T-cell clones. J Virol , 68(5): 3283-3288
13	Monath T P (2007). Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med , 357(22): 2222-2225
14	Rothman AL (2004). Dengue: defining protective versus pathologic immunity. J Clin Invest , 113: 946-951
15	Shekhar C (2007). Deadly Dengue: New Vaccines Promise to Tackle This Escalating Global Menace. Chem Biol , 14(8): 871-872
16	Sun W, Edelman R, Kanesa-Thasan N, Eckels K H, Putnak J R, King A D, Houng H S, Tang D, Scherer J M, Hoke C H Jr, Innis B L (2003). Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg , 69(6 Suppl): 24-31
17	Whitehead SS, Blaney J E, Durbin A P, Murphy B R (2007). Prospects for a dengue virus vaccine. Nat Rev Microbiol , 5(7): 518-528
18	Wilder-Smith A, Deen J L (2008). Dengue vaccines for travelers. Expert Rev Vaccines , 7(5): 569-578
19	Young P R, Hilditch P A, Bletchly C, Halloran W (2000). An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol , 38(3): 1053-1057

[1]	Andrew Brandmaier, Sheng-Qi Hou, Sandra Demaria, Silvia C. Formenti, Wen H. Shen. PTEN at the interface of immune tolerance and tumor suppression[J]. Front. Biol., 2017, 12(3): 163-174.
[2]	Jodi A. Gullicksrud, Qiang Shan, Hai-Hui Xue. Tcf1 at the crossroads of CD4⁺ and CD8⁺ T cell identity[J]. Front. Biol., 2017, 12(2): 83-93.
[3]	William J. ROBERTS, Georgianna G. SERGAKIS, Li ZUO. The role of human rhinovirus in immunology, COPD, and corresponding treatments[J]. Front Biol, 2013, 8(4): 377-386.
[4]	Xinghong YANG, Jerod A. SKYBERG, Ling CAO, Beata CLAPP, Theresa THORNBURG, David W. PASCUAL. Progress in Brucella vaccine development[J]. Front Biol, 2013, 8(1): 60-77.
[5]	Priyanka B. SUBRAHMANYAM, Tonya J. WEBB. Boosting the immune response: the use of iNKT cell ligands as vaccine adjuvants[J]. Front Biol, 2012, 7(5): 436-444.

Viewed

Full text

Abstract

Cited

Shared

Discussed